Meridian Bioscience Launches Lyo-Ready Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays
CINCINNATI, May 17, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the continued expansion of its isothermal amplification product line with the launch of two new innovative master mixes, Lyo-Ready Direct DNA LAMP Saliva Mix and Lyo-Ready Direct RNA/DNA LAMP Saliva Mix. The […]
MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS
CINCINNATI, May 6, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectations Life Science segment delivered record net revenues of $70.1 million […]
Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production […]
Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter
CINCINNATI, April 7, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022. Preliminary unaudited net revenues for the second quarter of fiscal 2022 are expected to be between $109 million and $113 million, above Meridian’s expectations […]
Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer
CINCINNATI, Ohio, Feb. 21, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Andy Kitzmiller joined Meridian Bioscience as Executive Vice President and Chief Financial Officer, reporting directly to CEO Jack Kenny. He will oversee the global finance organization and financial activities, including accounting and controllership, financial […]
Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits
CINCINNATI, Feb. 16, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Magellan Diagnostics resumed manufacturing and distribution of their LeadCare® II test kits. The Magellan quality management system identified discrepancies in the performance of LeadCare test kits. It was originally suspected that a defect […]
MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY
CINCINNATI, Feb. 4, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021. First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021): Consolidated net revenues of $88.3 million, second best in company history with both segments ahead of expectations Life Science segment delivered net revenues of $55.1 million Diagnostics […]
Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel
CINCINNATI, Jan. 31, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has been awarded additional funding in the amount of $2.5M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) initiative. This award expands the scope of the original $5.5M award to […]
Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection
CINCINNATI, Jan. 28, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude saliva samples. These two new mixes, Lyo-Ready Direct DNA qPCR Saliva Mix and Lyo-Ready Direct RNA/DNA qPCR Saliva Mix can […]
Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board
CINCINNATI, Jan. 27, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that John C. McIlwraith has been elected as Chairman of the Meridian Board of Directors, effective January 26, 2022. Mr. McIlwraith succeeds David C. Phillips, who retired after serving for more than 21 years on the Meridian […]